Zogenix stock: buy or sell?
September 20th, 2019
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States.
Should I buy Zogenix stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Zogenix stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Zogenix stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 15 ratings published for ZGNX stock in the last month. The general sentiment of these ratings is bullish for ZGNX stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-4-9||Piper Jaffray Companies||Overweight||Overweight|
Zogenix stock analysis
Shares of Zogenix closed today at $41.43 and stayed stable a tight 0.17%.
Zogenix stayed steady a tight 0.17% and closed at $41.43. Since Aug 27th when ZGNX stock price broke down the SMA200d line, it slid $-4.36 per share (-9.52%).
Zogenix shares declined -0.48% this week, ending at $41.43. Late August ZGNX collapsed a dreadful -17.15% in just one week.
Since price and 40-weeks moving average lines crossed down late August, ZGNX fell $-8.58 per share (-17.16%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.
Zogenix stock price history
Zogenix stock went public on November 23rd, 2010 with a price of $40.001. Since then, ZGNX stock surged a 3.60%, with an average of 0.50% per year. If you had invested right after ZGNX's IPO a $1,000 in Zogenix stock in 2010, it would worth $36.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Zogenix stock historical price chart
ZGNX stock reached 52-week highs on March at $56.50, and all-time highs 2018-07-13 with a price of 62.75.
Zogenix stock price target is $62.60Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' ZGNX stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 12 price predictions for Zogenix stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-4-9||Svb Leerink||Lowers Target||$60.00||$48.00||-20%|
|2019-4-9||Stifel Nicolaus||Lowers Target||$72.00||$61.00||-15.3%|
|2019-4-9||Piper Jaffray Companies||Lowers Target||$72.00||$68.00||-5.6%|
|2019-4-5||Northland Securities||Set Price Target||n/a||$70.00||-|
|2019-3-19||Northland Securities||Set Price Target||n/a||$70.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareZogenix disappointed experts on February when it reported an Earnings per Share (EPS) of $-0.53 when the analysts' forecast was $-1.00.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2017, Zogenix annual sales plummed a bloodcurdling -65.96% to $9.82 M USD from $28.85 marked in 2016. When comparing 2017 vs 2016, likewise, profit margin (that is, the net income divided by revenues) plunged a -1,049.67% to -1,291.28%.
|2013||$33 M||-||$-80.86 M-245.0%||-|
|2014||$41 M||22.78%||$8.59 M21.2%||-110.62%|
|2015||$27 M||-32.94%||$26 M96.2%||204.46%|
|2016||$29 M||6.14%||$-69.71 M-241.6%||-366.63%|
|2017||$9.82 M||-65.96%||$-126.82 M-1291.3%||81.93%|
Quarterly financial resultsReported quarter earnings marked $-22.43 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Zogenix sales marked a neutral move and stayed constant a nan%. Looking back to recent quarterly results, Zogenix posted 6 positive quarters in a row.
|2017-Q1||$2.70 M||-||$-21.13 M-782.6%||-|
|2017-Q2||$7.13 M||164.07%||$-22.45 M-314.9%||6.25%|
Zogenix ownershipWhen you are planning to invest in shares of a stock, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Zogenix, 2.92% of all outstanding shares are owned by its staff.
Bearish positions for ZGNX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Zogenix:
|Market cap||$1.8 B||$3.3 B||$590.3 M||$14.3 B||$364.7 M|
|Total shares||42.5 M||157.1 M||163.1 M||298.1 M||191.9 M|
|Float shares||31.5 M||155.3 M||150.5 M||296.9 M||166.6 M|
|- Institutional holdings (%)||116.2%||99.2%||42.3%||92.4%||46.1%|
|- Insider holdings (%)||2.9%||0.9%||7.3%||0.3%||4.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$40.88 - $41.58|
|Average true range||$1.51|
|50d mov avg||$46.33|
|100d mov avg||$43.47|
|200d mov avg||$44.24|
Zogenix performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Zogenix, the benchmark is made against Alkermes, Antares Pharma, Cardinal Health, DURECT, , Eli Lilly and, Mallinckrodt, Merck, Nektar and Pfizer.
|LLYEli Lilly and||-0.44%||-9.87%||9.89%|